KRAS G12D Mutation: Biology, Testing and Context
KRAS G12D replaces glycine with aspartate at codon 12. Like other oncogenic KRAS variants, it can impair the normal off-switching cycle of the KRAS protein, but it should be interpreted as part of a tumour's full molecular and clinical context.
Quick Answer
KRAS G12D replaces glycine with aspartate at codon 12. Like other oncogenic KRAS variants, it can impair the normal off-switching cycle of the KRAS protein, but it should be interpreted as part of a tumour's full molecular and clinical context.
The KRAS Molecular Switch
KRAS cycles between GDP-bound and GTP-bound conformations. Codon-12 substitutions can impair GTP hydrolysis and increase signalling through downstream networks such as RAF–MEK–ERK and PI3K–AKT.
G12D identifies an amino-acid substitution, not a single biological outcome. Its effects are shaped by tissue type, co-mutations and regulatory feedback in the tumour.
Reading a KRAS G12D Report
A report may include the DNA notation, protein notation, variant allele fraction, assay and specimen source. Each helps describe the measurement, but none alone establishes tumour burden or a treatment plan.
Confirm that the finding is in KRAS, the transcript used and whether the sample was tumour tissue or blood. Somatic testing answers a different question from inherited-risk testing.
Key Takeaways
- ·G12D is a codon-12 KRAS substitution that can favour sustained signalling.
- ·KRAS variants are not biologically interchangeable.
- ·Interpret the variant with the tumour type, co-alterations and assay details.
Put these genes in pathway context
Frequently asked questions
What is the key idea in KRAS G12D Mutation: Biology, Testing and Context?
KRAS G12D replaces glycine with aspartate at codon 12. Like other oncogenic KRAS variants, it can impair the normal off-switching cycle of the KRAS protein, but it should be interpreted as part of a tumour's full molecular and clinical context.
What should be kept with the result or mechanism?
G12D is a codon-12 KRAS substitution that can favour sustained signalling. KRAS variants are not biologically interchangeable. Interpret the variant with the tumour type, co-alterations and assay details.
References
Continue Reading
KRAS G12C vs G12D: Similar Gene, Different Alterations
2 min read
KRAS G12V Mutation: How to Interpret the Finding
2 min read
KRAS Mutations: Constitutive MAPK Signalling and Targeted Therapy
6 min read
BRAF V600E in Cancer: Mechanism and Targeted Treatment
4 min read
EGFR Exon 19 Deletions: What the Biomarker Means
4 min read
EGFR L858R: Understanding the Exon 21 Mutation
3 min read
Choose your next research step
Move from this explanation into a gene profile, a pathway map, or the next evidence update.
KRAS has 500+ trials currently recruiting on ClinicalTrials.gov. The GeneAnalyses digest summarises the new and changed ones each day.